11170 RESULTS
COMMENT My thoughts are that this as a very interesting approach. It capitalizes on our understandings of the populations of neurons that are (and are not) vulnerable to degeneration in Parkinson's disease, and uses relatively recent but now well developed m
COMMENT Nitric oxide signaling via the second messenger molecule cGMP is essential for normal physiological brain function. NO itself is produced by the NO synthase (NOS) family of enzymes, and NO bioactivity is also exerted by metabolites of NO and by cGMP-indep
COMMENT This study by Eckman and colleagues elegantly shows how instructive pharmacology and genetics can be in understanding, and perhaps preventing, a complex disease. Using vasopeptidase inhibitors already used or in development for the clinic, the authors dem
COMMENT There have been many reports of peptide sequences as anti-amyloidgenic agents; so far all of them failed in vivo. Therefore crucial questions are: do these peptides make it into the brain? are the orally available? is fibril disruption still a target? are
COMMENT The work is sound, yet the title of the paper gives a bad taste to it. The potency of the most active peptide holds promise as a tool in AD research. The title claims lead qualities for a peptide, which ignores the "lead" standards of most pharm
COMMENT Is there any evidence of pancreatitis prior to the development of AD which may explain the large weight loss which is reported to occur several years prior to AD? It's of interest that HSF-1 is activated in acute pancreatitis (1) and β-APP is activat
COMMENT cation-independent mannose-6 phosphate receptor (3,4). See also: Comment by Mary Reid emaryreid 0 The human
COMMENT This paper presents interesting but preliminary data showing an increased E4 frequency in patients with "memory phenotype" of AD compared to the "non-memory" phenotype where patients presented with, for example, agnosia or apraxia. Imp
COMMENT This report by Kantarci et al. is a welcome addition to the literature on neuroimaging measures that are of potential interest in diagnosis and charting of the longitudinal course of mild cognitive impairment (MCI). The authors used single voxel proton ma
COMMENT This study builds upon existing genotyping and combines studies to provide a compelling confirmation of the well-reported association between allele length of the promoter polymorphism REP1 in α-synuclein (SNCA) and risk for Parkinson disease (1-5). These
COMMENT This work confirms the association between synuclein and Parkinson disease (PD), which has been reported many times and complements a recent and excellent paper from the Gasser group. As with all meta-analyses, however, one has to worry that publication b
COMMENT This paper attempts to address two important questions that stem from the “amyloid cascade” model of Alzheimer pathology: why is AD age-dependent, and which specific forms of the β amyloid peptide (Aβ) are responsible for the toxicity? The experimental mo
COMMENT Several recent studies, including the large, NIH-sponsored Alzheimer’s Disease Neuroimaging Initiative, have been launched to clarify the utility of using different imaging modalities as potential surrogate markers for disease processes. Considerable exci
COMMENT An Intramitochondrial Aβ-cleaving Peptidase After identifying human PreP, a mitochondrial zinc-binding metalloendopeptidase that degrades targeting peptides as well as other unstructured peptides within mitochondria, these authors further demonstrated tha
COMMENT This paper is interesting because it describes some of the structural differences between Aβ fibrils and oligomers, and there is very little known about oligomer structure. The data indicate that while some regions are similarly disordered in fibrils and
